EP Patent

EP3886820B8 — Capsule formulations

Assigned to Chemocentryx Inc · Expires 2023-05-17 · 3y expired

What this patent protects

Patent listed against Tavneos.

Drugs covered by this patent

Tavneos (AVACOPAN) · Chemocentryx

Patent Metadata

Patent number: EP3886820B8
Jurisdiction: EP
Classification: —
Expires: 2023-05-17
Drug substance claim: No
Drug product claim: No
Assignee: Chemocentryx Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.